FDA Class III Recall: STAQ Pharma's Ketamine Injection Faces Labeling Non-Compliance
STAQ Pharma, Inc. has initiated a nationwide Class III recall of Ketamine Hydrochloride Injection due to critical labeling errors concerning lot and expiration dates. This event signals a lapse in GMP, requiring immediate action from procurement and regulatory teams to assess supply chain integrity and ensure compliance with labeling standards for critical medications like Ketamine.
FDA Mandates Class III Recall for STAQ Pharma's Ketamine Hydrochloride Injection
The U.S. Food and Drug Administration (FDA) has classified a firm-initiated recall (D-0024-2026) by STAQ Pharma, Inc. for specific lots of its Ketamine Hydrochloride, 50mg/5 mL (10mg/mL) Injection, supplied in 50 mL syringes. This Class III recall, voluntarily initiated by STAQ Pharma on October 9, 2025, and classified by the FDA on October 15, 2025, addresses critical labeling deficiencies: specifically, incorrect or missing lot and/or expiration dates on the product packaging. The affected product, identified by Lot #: 25156673A with an Expiry: 02FEB2026 and NDC 73177-0156-02, was distributed nationwide across the United States. While a Class III classification indicates that the use of or exposure to the violative product is not likely to cause adverse health consequences, it unequivocally points to a fundamental breakdown in Good Manufacturing Practices (GMP) related to labeling control. For procurement directors and supply chain VPs, this event necessitates immediate action. It requires a thorough audit of current inventory to identify and quarantine any affected lots of Ketamine Hydrochloride, preventing their inadvertent use or further distribution. Regulatory affairs heads must assess the potential for similar labeling non-conformities within their broader supply chains and review existing supplier quality agreements to ensure robust controls over critical labeling information. This incident underscores that even seemingly minor labeling errors can trigger significant operational disruptions, including product quarantines, returns, and potential stockouts if not managed with stringent quality oversight.
Operational Overview: STAQ Pharma's Denver Facility and Product Scope
STAQ Pharma, Inc., operating from its facility at 14135 E 42nd Ave Ste 50, Denver, CO 80239-5214, United States, is the manufacturer responsible for the recalled Ketamine Hydrochloride Injection. This facility plays a role in the domestic supply of injectable pharmaceuticals, with the recalled product, Ketamine, being a critical anesthetic and analgesic widely used in various medical settings. The nationwide distribution pattern of the affected lots highlights the broad reach of STAQ Pharma's products within the U.S. healthcare system. The recall specifically targets a 50 mL syringe presentation, a common format for hospital and clinical use. For business development executives, understanding the operational footprint of key suppliers like STAQ Pharma is crucial. While the specific capacity or market share of this facility is not detailed in the available information, its role in supplying a vital medication across the U.S. means any disruption, even a Class III recall, has ripple effects. Supply chain VPs must recognize that reliance on a single facility for critical drug components or finished products introduces inherent risks. This event serves as a reminder to scrutinize the geographical concentration of suppliers and to evaluate the resilience of supply chains against localized quality control issues, even within domestic manufacturing bases.
Supply Chain and Procurement Implications for Ketamine Sourcing
The recall of Ketamine Hydrochloride Injection by STAQ Pharma due to labeling inaccuracies carries direct implications for procurement teams and supply chain management across the U.S. healthcare sector. Ketamine is an essential medicine, and any disruption to its supply, regardless of the recall classification, demands immediate attention. Procurement directors must initiate rapid internal investigations to verify the integrity of all received Ketamine shipments from STAQ Pharma, cross-referencing lot numbers (specifically 25156673A) and expiration dates (02FEB2026) against internal records and the recall notice. Any identified affected product must be immediately quarantined and returned according to STAQ Pharma's instructions. Beyond immediate action, this incident underscores the necessity for rigorous supplier qualification and ongoing monitoring programs. Regulatory affairs heads must ensure that their organizations are fully compliant with recall procedures, including accurate record-keeping and communication with relevant healthcare providers. Business development executives should note that such recalls can impact supplier reputation and future contracting opportunities. The administrative burden of managing a recall, from inventory checks to regulatory reporting, can be substantial, emphasizing the commercial imperative for suppliers to maintain impeccable quality control, particularly for critical labeling elements that are fundamental to patient safety and product traceability.
Mitigating Supply Risk: Strategic Sourcing and Supplier Qualification
In light of STAQ Pharma's Ketamine Hydrochloride recall, procurement teams must re-evaluate their strategies for mitigating supply chain risks, especially for essential injectable drugs. While specific alternative suppliers are not identified in the available intelligence, the principle of supply diversification remains paramount. Companies should actively pursue multi-sourcing strategies for critical APIs and finished drug products to reduce dependency on a single manufacturer or facility. This involves identifying and pre-qualifying backup suppliers, ideally from geographically diverse regions, to build resilience against localized quality issues or regulatory actions. Qualifying new suppliers for injectable pharmaceuticals, such as Ketamine, is a complex and time-consuming process. It typically involves extensive due diligence, including on-site cGMP audits, comprehensive analytical testing, stability studies, and regulatory dossier preparation, often taking 6 to 18 months. Therefore, proactive identification and qualification of alternative sources are crucial, rather than reactive measures during a supply disruption. Supply chain VPs should prioritize investments in robust supplier relationship management and quality management systems that extend to third-party manufacturers, ensuring that all aspects of production, including critical labeling, adhere to the highest regulatory standards. This strategic approach minimizes the commercial impact of recalls and ensures continuity of patient care.
Regulatory Compliance Trends and Industry Vigilance for Labeling Accuracy
While the available intelligence does not detail prior regulatory actions specifically against STAQ Pharma, Inc., this recall occurs within a broader landscape of heightened FDA scrutiny across the pharmaceutical industry. Recent parallel events, such as Essential Wellness Pharma's Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and the FDA's hearing on Amgen's Tavneos market future amidst independent data review, underscore the agency's persistent focus on diverse aspects of Good Manufacturing Practices (GMP), including sterility, data integrity, and, as seen with STAQ Pharma, labeling accuracy. For regulatory affairs heads, this trend signals that no aspect of pharmaceutical manufacturing is immune from regulatory oversight. Labeling, often perceived as a downstream process, is a critical component of product quality and patient safety. Incorrect or missing lot and expiration dates can lead to the use of expired or untraceable products, posing significant risks. Business development executives must understand that a strong compliance record is a competitive advantage, while repeated or severe compliance issues can lead to escalated enforcement actions, including Warning Letters, Import Alerts, and significant market access restrictions. Maintaining continuous vigilance over internal quality systems and those of contract manufacturing organizations (CMOs) is essential to navigate this evolving regulatory environment and safeguard market standing.